More Than 300 Companies Adopt Vault Quality Applications to Unify Global Quality Processes

Veeva Systems (NYSE: VEEV) today announced increasing numbers of biopharma, contract services, generics, and medical device and diagnostics companies are adopting Veeva Vault Quality Suite applications to unify and modernize quality management globally. More than 300 organizations, including 13 of the 20 largest global pharmaceutical companies, use Veeva applications for managing quality processes, content, and training. Veeva’s rapid pace of innovation is delivering the industry’s most advanced and comprehensive suite of applications on a single cloud platform to streamline global quality processes.

“Veeva’s quality applications work together seamlessly and deliver continuous innovation based on our needs,” said Lexie Pieper, vice president, quality assurance at Celularity, Inc. “Veeva Vault Quality Suite gives us a powerful set of solutions so our organization has complete visibility into quality information and processes. We can’t wait to see the quality innovations Veeva delivers next.”

There is a growing need among life sciences organizations to bring together disconnected systems and incorporate internal and external stakeholders into quality processes. Companies can transform end-to-end quality management with Vault Quality applications, increasing collaboration and visibility across the enterprise.

Veeva continues to deliver innovations that help customers streamline quality content and processes across global sites, suppliers, contract manufacturers, and other partners. In less than three years, Veeva’s suite of quality applications has expanded to help customers adapt and respond quickly to changing business requirements, including:

• Vault Training to simplify role-based qualifications and training;
• Integrated change control and variation management across quality and regulatory using Vault QMS and Veeva Vault Registrations, as well as quality risk management in Vault QMS to identify and mitigate risks proactively;
• Vault Station Manager, a mobile application that provides up-to-date content directly to operators on the manufacturing floor;
• And Vault Product Surveillance to enable medical device and diagnostics companies to simplify and standardize the post-market surveillance process globally.

“Modernizing and unifying quality management has become a top priority across life sciences,” said Mike Jovanis, vice president of Vault Quality. “Veeva Vault Quality Suite is helping customers streamline business processes, increase operational efficiency, and drive greater agility throughout the product life cycle.”

The Vault Quality Suite includes Vault QMS, Vault QualityDocs, Vault Training, Vault Station Manager, and Vault Product Surveillance to automate and harmonize quality processes globally. Vault Registrations is part of Veeva Vault RIM, a suite with applications used by 12 of the top 20 global pharmaceutical companies to streamline end-to-end global regulatory processes.

In other news today, Veeva announced that Roche selected Veeva Development Cloud applications across clinical, regulatory, and quality. Read today’s press release for more information.

Learn more at the upcoming Veeva R&D and Quality Summit, October 13-14, 2020. The online event is open to life sciences industry professionals. Register and stay up to date on program details at veeva.com/Summit.

Additional Information
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems

About Veeva Systems

Veeva Systems Inc. is a leader in cloud solutions—including data, software, and services—for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 900 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. The company is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu.

Forward-looking Statements

This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended July 31, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

® 2020 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo are trademarks of Veeva Systems Inc.
Veeva Systems Inc. owns other registered and unregistered trademarks.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201012005224/en/

Contact information

Roger Villareal
Veeva Systems
925-264-8885
roger.villareal@veeva.com

Deivis Mercado
Veeva Systems
925-226-8821
deivis.mercado@veeva.com